Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
Table 1
Baseline characteristics.
All patients ()
Gender (, %)
Female
2 (29)
Male
5 (71)
Age (year; median, range)
53 (44–74)
Time from diagnosis (year; median, range)
4.3 (1.6–25.6)
Initial TNM stage (, %)
IB (T2 N0 M0)
0
IIB (T2-3 N0-1 M0)
2 (29)
IIIA (T1-3 N1-2 M0)
3 (43)
IV (any T any N M1)
2 (29)
Unknown
0
Tumor extent at study entry (, %)
Locally advanced
1 (14)
Metastatic
6 (86)
Number of disease sites (, %)
1
1 (14)
2
2 (29)
≥3
4 (57)
Mutational status (, %)
RET M918T
4 (57)
MEN-IIA
1 (14)
EGFR P848L
1 (14)
Unknown
1 (14)
Prior treatment (, %)
Surgery
6 (86)
Radiation therapy
2 (29)
Tyrosine kinase inhibitor
4 (57)
3 patients received XL184; 1 patient showed an ongoing PR for 14 months before he became progressive; 2 had PD as best result after 12 and 24 weeks. 1 patient had vandetanib for 8 months, followed by 3 months of sunitinib, which was stopped due to side effects.
